Navigation Links
IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
Date:12/14/2007

nd to all of the questions and requests for additional information received from FDA, the Company now anticipates it will likely take until the second half of 2008 to prepare the amendment to the new drug application (NDA) for L-MTP-PE.

Given the significant additional time and cost that would need to be incurred in order to collect the patient data and respond to regulatory agency comments on the filings for L-MTP-PE, the Company's board of directors authorized management to work with the Company's investment bank, JMP Securities, to evaluate the Company's research and development programs, including related assets and costs, and strategic alternatives available to the Company.

"We, along with key opinion leaders in the United States and Europe, continue to strongly believe in the survival benefit offered by L-MTP-PE in osteosarcoma patients, a devastating disease where there hasn't been a treatment advance in more than 20 years," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "Based on the current status of the lead program and an evaluation of the timing, potential costs and risks involved in continuing with current clinical plans, we believe it is prudent to manage our cash burn at this time and to pursue strategic alternatives that would potentially preserve the value of our lead program assets without undue risks."

Additional Clinical Updates

UVIDEM(R)

The next planned step in the UVIDEM development program is a Phase 2, open-label, randomized study of UVIDEM designed to evaluate patients with in-transient or low volume metastatic melanoma in the next 60 days. Patients will receive UVIDEM or UVIDEM plus low-dose cyclophosphamide and treatment(s) will continue for a maximum of two years. The primary endpoint will be progression-free survival and secondary endpoints include tumor response, safety and immune monitoring. The study is designed to enroll 82 patients at sites in the United States and Eur
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 According to a new ... Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - ... 2013-2019" the global endoscopy devices market was valued at ... grow at a CAGR of 6.8% from 2013 to ... billion in 2019. Browse the full Endoscopy ...
(Date:7/10/2014)... India , July 11, 2014  Major ... treatment of cancer are being highlighted in a ... Mumbai from 10-12 July, 2014.  Renowned national ... to share best practices and exchange knowledge on ... precise, accurate and efficient. The ...
(Date:7/10/2014)...  RESMED INC. (NYSE: RMD ) today announced ... ended June 30, 2014 results on Thursday, July 31, 2014, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Soligenix, Inc. (OTC Bulletin Board: SNGX ) ... today that it has appointed Kevin Horgan, MD, as ... Horgan is a board-certified gastroenterologist with a research background ... patients with inflammatory bowel disease, including graft-versus-host disease (GVHD). ...
... JOLLA, Calif., Feb. 1, 2011 Transdel Pharmaceuticals, ... a specialty pharmaceutical company focused on developing topically ... announced that the Company has been exploring strategic alternatives ... American MedTech Advisors and ESC Advisors, a division ...
Cached Medicine Technology:Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 2Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 3Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 4Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 2Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 3
(Date:7/11/2014)... Steven Reinberg HealthDay ... A potential vaccine to protect children from the worldwide scourge ... Asian children. While the vaccine only prevented dengue fever ... full series of three shots, it protected more than 88 ... dengue fever can lead to hospitalization, and sometimes death. ...
(Date:7/11/2014)... 11, 2014 Ticket Down is ... the Sleep Train Amphitheatre in Wheatland, CA. In ... compare to what the Sleep Train Amphitheatre can do for ... special attractions over the course of its existence and can ... Train Amphitheatre in Wheatland (Sacramento metro area) will host the ...
(Date:7/11/2014)... 2014 Europe is one of the ... cultivated-and hence, irrigated land area. The agricultural sector is ... for around 30.0% of the total water use. The ... the southern region, but far from negligible in most ... for over 60.0% of the water use in most ...
(Date:7/11/2014)... years scientists have been trying to unravel mechanisms that ... cells that generate all blood cells including our immune ... difficult because they can only be found in the ... in a culture dish. Now a group of scientists ... Waskow (Technische Universitt Dresden) was able to generate a ...
(Date:7/11/2014)... Mexico (PRWEB) July 11, 2014 Experience ... the Mayan Heritage Experience Package at the luxury all-inclusive ... the package include a guided on-site ecological family tour ... well as The Coba Mayan Encounter Tour at the ... Nohoch Muul, the tallest pyramid in the Yucatan and ...
Breaking Medicine News(10 mins):Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3Health News:Opening-up the stem cell niche 2Health News:Explore the Aura and Mystery of the Yucatan’s Mayan Culture with New Hotel Package at AAA Five Diamond Grand Velas Riviera Maya 2Health News:Explore the Aura and Mystery of the Yucatan’s Mayan Culture with New Hotel Package at AAA Five Diamond Grand Velas Riviera Maya 3
... (HealthDay News) -- Inadequate sleep and the absence of a ... of primary school children, research shows. When 6-year-old ... hours each night, their academic skills suffer along with their ... sleep less than is recommended for their intellectual development, which ...
... , FRIDAY, Sept. 16 (HealthDay News) -- People ... clotting and inflammation have a lower five-year survival rate ... findings should be used to better treat and ensure ... said the research team from Duke University Medical Center ...
... , FRIDAY, Sept. 16 (HealthDay News) -- Fall-prone older ... because they don,t slow their walking speed when their vision ... Fiona Newell of Trinity College in Dublin and colleagues, looked ... in the past year, six older adults who had not ...
... Sept. 16 (HealthDay News) -- People with dementia appear to ... nursing homes because they offer a domestic environment where patients ... And small group homes offer the added benefit of allowing ... pointed out in the study published in the September issue ...
... News) -- When people are hungry, they are more likely ... the reason why: serotonin levels -- a hormone that helps ... haven,t eaten, according to a new study. Rising ... allow people to control their anger, researchers from the University ...
... Scientists (AAPS) WHAT: , Scientists from around the ... discoveries in order to improve health through advances in pharmaceutical ... In recognition of AAPS,s 25th anniversary this year,s meeting, "The ... including more than 60 symposia and roundtables. WHEN: ...
Cached Medicine News:Health News:Lack of Sleep Hurts Kids' Academic Performance: Study 2Health News:Gene Variant May Raise Death Risk After Heart Bypass 2Health News:Dementia Patients Seem to Benefit From Small Group Homes 2Health News:Research Reveals Why Hungry People Get Cranky 2
... you sleep on your dry ... morning awake with your eyes ... take on the day. Ideal ... protection, this preservative-free lubricant eye ...
... New REFRESH LIQUIGEL® Lubricant Eye Drops ... with the convenience of a liquid ... protection. Its extra-strength CMC formula provides ... comfort. And with the PURITE® preservative, ...
... ophthalmic solution is an anti-infective ... doctor may instruct you to ... eye infection caused by bacteria. ... are the 2 types of ...
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
Medicine Products: